The use of private tech firm Palantir to power the National Health Service's (NHS) Federated Data Platform (FDP) has raised eyebrows among campaigners and critics who argue that the government is overstating its benefits. Despite some positive claims, there remains a lack of robust evidence to prove the FDP has led directly to improved NHS outcomes or patient care.
The FDP was designed to integrate data from various NHS sources, allowing for better management of hospital waiting lists, optimisation of bed allocation and identification of health inequalities. Palantir's involvement in building this platform has sparked concerns about data privacy and the role of private companies in public healthcare. Critics point out that while the vision for the FDP is ambitious, ministers' claims of success are not adequately backed by independent evidence.
NHS England and the Department of Health and Social Care have maintained that the FDP will revolutionise NHS operations, leading to more efficient services and better patient outcomes. However, concerns persist over the lack of transparency regarding how the platform delivers these benefits – specifically, what metrics are being used to measure its success.
Opposition parties have added their voices to those calling for greater accountability in the implementation and evaluation of the FDP. They stress that any technology introduced into the NHS must demonstrate clear, quantifiable benefits for patients and staff, and that public funds should be spent wisely and accountably.
The NHS's reliance on private tech firms like Palantir has also raised questions about data security and patient confidentiality. While these concerns are not directly addressed in the government's claims of success regarding the FDP, they will likely continue to influence debates around the platform's future.